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ABSTRACT 
Although iron-mediated oxidative stress has been proposed as a potential pathomechanism in 
Parkinson’s disease, the global distribution of iron accumulation in Parkinson’s disease has not yet 
been elucidated. This study used a new magnetic resonance imaging contrast, quantitative 
susceptibility mapping, and state-of-the-art methods to map for the first time the whole-brain 
landscape of magnetostatic alterations as a surrogate for iron level changes in N=25 idiopathic 
Parkinson’s disease patients versus N=50 matched controls. In addition to whole-brain analysis, a 
regional study including sub-segmentation of the substantia nigra into dorsal and ventral regions 
and qualitative assessment of susceptibility maps in single subjects were also performed. The most 
remarkable basal ganglia effect was an apparent magnetic susceptibility increase—consistent with 
iron deposition—in the dorsal substantia nigra, though an effect was also observed in ventral 
regions. Increased bulk susceptibility, additionally, was detected in rostral pontine areas and in a 
cortical pattern tightly concordant with known Parkinson’s disease distributions of α-synuclein 
pathology. In contrast, the normally iron rich cerebellar dentate nucleus returned a susceptibility 
reduction suggesting decreased iron content. These results are in agreement with previous post-
mortem studies in which iron content was evaluated in specific regions of interest; however, 
extensive neocortical and cerebellar changes constitute a far more complex pattern of iron 
dysregulation than was anticipated. Such finding also stand in stark contrast to the lack of 
statistically significant group change using conventional magnetic resonance imaging methods 
namely voxel-based morphometry, cortical thickness analysis, subcortical volumetry and tract-
based diffusion tensor analysis; confirming the potential of whole-brain quantitative susceptibility 
mapping as an in vivo biomarker in Parkinson’s disease.  
 
INTRODUCTION 
Idiopathic Parkinson’s disease is a common progressive degenerative disorder characterised 
pathologically by proteinaceous aggregates of α-synuclein in the form of Lewy bodies and Lewy 
neurites. These are thought to occur early in the brainstem, gradually spreading across vulnerable 
sites in the allocortex and temporal paralimbic cortex before reaching prefrontal and sensory-
association isocortex (Braak et al., 2004). It is postulated that projection neurons with 
disproportionally long, thin and poorly myelinated axons are particularly susceptible to 
degeneration in Parkinson’s disease (Braak et al., 2004), of which the most studied to date have 
been the neuromelanin-pigmented dopaminergic neurons of the basal ganglia. It should be noted, 
however, that the mechanisms that render certain neuronal populations vulnerable to degeneration 
are unclear; furthermore, the motor dysfunction in Parkinson’s disease related to nigrostriatal 
degeneration is only one aspect of this multi-faceted disease that includes numerous non-motor 
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manifestations. As such, new in vivo approaches to identify possible pathomechanisms across the 
entire Parkinson’s disease brain are highly desirable. 
 
One such potential mechanism is oxidative stress due to excessive brain iron accumulation. 
In the aging brain, this has been implicated in neurotoxicity, mitochondrial dysfunction and chronic 
inflammation, as well as promotion of α-synuclein aggregation and dopaminergic alterations (Sian-
Huelsmann et al., 2011; Ayton and Lei, 2014). The relevance of iron in the pathogenesis of 
Parkinson’s disease lies in its capacity to generate free-radical species that may act in concert with 
α-synuclein to induce Lewy pathology (Ostrerova-Golts et al., 2000; Li et al., 2011), and may 
catalyse dopamine oxidation reactions that exacerbate the formation of other neurotoxic by-
products (Hare and Double, In Press, DOI: 10.1093/brain/aww022, available online 8 March 2016). 
The study of brain iron, however, is particularly challenging due to its ubiquitous involvement in 
numerous biological processes (Ward et al., 2014). Under normal conditions, it is well established 
that a high proportion of brain iron is bound to ferritin in the redox-inactive ferric state (Hallgren 
and Sourander, 1958), whereas only small quantities of redox-active ferrous iron are required to 
ensure a readily available supply of labile iron for cellular metabolism. It is thus largely assumed 
that all mechanisms involving iron management, i.e. transport, uptake, storage, efflux and 
redistribution, must be stringently regulated to prevent free ferrous iron from indiscriminately 
catalysing additional unwanted toxic reactions. To date, however, we lack conclusive evidence 
incriminating free-iron mediated mechanisms as a primary cause rather than a secondary 
consequence of neurodegeneration in Parkinson’s disease. Nonetheless, numerous studies have 
confirmed iron elevation in the substantia nigra pars compacta of post-mortem brains using 
histochemical (Dexter et al., 1991; Sofic et al., 1991) and X-ray methods (Popescu et al., 2009), 
and in vivo, employing semi-quantitative iron-sensitive techniques such as transcranial sonography 
and magnetic resonance imaging (MRI) – reviewed elsewhere (Groeger and Berg, 2012); an 
increase that might lead to iron-mediated toxic interactions in Parkinson’s disease. Thus far, 
however, iron analyses have been limited to regions of interest, and though several brain areas 
beyond the substantia nigra have been identified as having increased (Griffiths et al., 1999) or 
decreased (Dexter et al., 1991; Popescu et al., 2009) iron content, the global distribution of iron 
dysregulation in Parkinson’s disease has not yet been elucidated. The present study utilised 
quantitative susceptibility mapping or QSM—a newly validated, iron-sensitive MRI measure 
(Langkammer et al., 2012; Zheng et al., 2013; Sun et al., 2015)—to describe the whole-brain 
distribution of magnetostatic alterations in Parkinson’s disease, and contrasted these results with 
those from “standard” structural and microstructural MRI markers, none of which, however, probes 
the integrity of the substantia nigra. 
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MATERIALS AND METHODS 
Study subjects 
N=25 clinically definite idiopathic Parkinson’s disease patients according to UK Parkinson’s 
Disease Brain Bank criteria (Hughes et al., 1992) were recruited from the specialist movement 
disorder clinic of the Otto von Guericke University Neurology Department. All patients had their 
clinical assessments in the ‘on’ state with respect to anti-Parkinsonian medication with the 
exception of one mild, drug-naïve, tremor-dominant individual who wished to delay commencing 
therapy until symptoms worsened. For imaging comparisons, N=50 healthy control subjects—a 
subset of a larger, previously studied, aging cohort (Acosta-Cabronero et al., 2016)—were twice-
paired for age while keeping a non-significant sex ratio. All controls performed normally on 
cognitive screening, mini-mental state examination or MMSE (Folstein et al., 1975), and had no 
history of neurological disease. Group demographic details are summarised in Table 1. 
 
Table 1. Study demographic details. 
 Control (N=50) Parkinson’s disease (N=25) 
Sex (male:female) 28:22 20:5 [χ2=9.7, NS] 
Age (years) 63.6 (8.5) 63.6 (8.6) 
Disease duration (years) NA 6 (4) 
MMSE (≤30) 29.0 (0.9) 26.7 (3.0) 
UPDRS-III (≥0) NA 16.3 (8.0) 
Tremor dominant/akinetic-rigid 
dominant/mixed (N, %) NA 12/52/36 
Modified Hoehn & Yahr stage (≥1) NA 2.2 (0.3) 
Levodopa equivalent dose (mg) NA 748 (434) 
Where appropriate values are given as mean (standard deviation); not significant (NS, P>0.01); not 
applicable (NA); mini-mental state examination (MMSE); on-medication, unified Parkinson’s 
disease rating scale – motor evaluation (UPDRS-III). 
 
Prior to inclusion in the study, which was approved by the ethics committee at Otto-von-Guericke 
University, subjects gave their written informed consent according to the Declaration of Helsinki. 
 
Imaging protocol 
The imaging protocol and processing methods used in this study are identical, except for the 
addition of diffusion tensor imaging (DTI), to those developed and optimised for a previous aging 
study (Acosta-Cabronero et al., 2016), which are summarised below: 
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MRI measurements were performed on a Siemens Verio 3 Tesla system (Siemens, Erlangen, 
Germany) with a standard Siemens 32-channel receive array coil.  
 
Susceptibility weighting was sensitised with a three dimensional, flow-compensated, spoiled 
gradient-echo pulse sequence: flip angle was 17°; echo time, 20 ms; receiver bandwidth, 100 Hz per 
pixel; and repetition time, 28 ms. Matrix size was 256×224×80, with slices in straight-axial 
orientation (0.4-mm inter-spacing and 20% oversampling to reduce crosstalk effects and aliasing 
artifacts, respectively), and voxel resolution of 1×1×2 mm3. GRAPPA, the technique of generalised 
autocalibrating partially parallel acquisitions (Griswold et al., 2002), was used with acceleration 
factor of 2 and 24 reference lines, giving a scan time of 5:32 minutes.  
 
MPRAGE (magnetisation-prepared, three dimensional, rapid gradient-echo) anatomical images 
were also acquired with the following acquisition parameters: inversion time was 1100 ms; flip 
angle, 7°; echo time, 4.37 ms; receiver bandwidth, 140 Hz/pixel; echo spacing, 11.1 ms; and 
repetition time, 2500 ms. Matrix dimensions were 256×256×192 (0.5-mm inter-slice gap), 7/8 
partial Fourier, and 1×1×1 mm3 voxel size. GRAPPA was also enabled with acceleration factor of 2 
and 24 reference lines. To aid co-registration, the field of view was prescribed consistent with the 
susceptibility-weighted scan, i.e. with slices in straight-sagittal orientation. 
 
T2-weighted turbo spin echo images were also acquired in the same scanning session, and were 
visually inspected to ensure vascular pathology—as for standard clinical practice—was not 
significant in any subject. To facilitate visual inspection, the field of view was aligned at acquisition 
to the anterior commissure–posterior commissure line. Scan parameters were: flip angle, 150°; echo 
time, 96 ms; receiver bandwidth, 220 Hz/pixel; turbo factor, 18; 13 echo trains with echo spacing, 
9.64 ms; and repetition time, 8160 ms. In-plane matrix was 320×320 (resolution: 0.7×0.7 mm2) for 
45 axial slices (thickness: 3 mm; gap: 0.9 mm); GRAPPA factor of 2 with 51 reference lines. 
 
Diffusion MRI data was acquired using a twice-refocused, single-shot echo-planar imaging pulse 
sequence: repetition/ echo time = 9000/ 94 ms; matrix, 120×120; 63 contiguous slices aligned 
parallel to the anterior commissure–posterior commissure line; voxel size: 2×2×2 mm3; 7/8-phase 
partial Fourier; bandwidth of 1667 Hz/pixel and echo spacing of 0.68 ms. Diffusion gradients were 
applied along 30 non-collinear directions with two non-zero b-values (b=700 and 1000 s/mm2), and 
12 interleaved reference scans. Parallel imaging was enabled (GRAPPA, acceleration factor of 2 
and 38 reference lines) for a total scan time of 11:15 minutes. 
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A thin pillow was placed on the base of the coil surrounding the sides and the back of the head to 
minimise motion and increase inter-subject reproducibility in positioning. 
 
Structural MRI statistical analyses 
Voxel-based morphometry. VBM was performed in SPM12b v6080 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12) with default settings. Following “unified 
segmentation” and “modulation”, grey matter segments were smoothed with an 8-mm full width at 
half maximum Gaussian kernel prior to statistical analysis – a two sample (Parkinson’s disease 
versus control) T-test controlling for total intracranial volume; the latter were determined using a 
previously validated method (Pengas et al., 2009).  
 
Cortical thickness analysis. A standard whole-brain routine for vertex-wise surface reconstruction, 
inflation, smoothing and statistical group analysis of cortical thickness was carried out in the 
FreeSurfer v5.3.0 framework (http://surfer.nmr.mgh.harvard.edu).  
 
Subcortical volumetry. Left and right thalamus, caudate nucleus, putamen, globus pallidus, 
hippocampus and amygdala were segmented automatically from radio-frequency bias-corrected 
MPRAGE images using the FIRST algorithm (Patenaude et al., 2011) – an automated surface-
aware method that incorporates prior anatomical knowledge (included in FMRIB’s software library, 
FSL v5.0.9). FIRST-derived region of interest volumes were normalised by total intracranial 
volume using a well-established covariance method (Jack et al., 1989). Finally, n=12 two-tailed 
Wilcoxon rank-sum tests of equal medians were performed to assess for group differences in each 
region of interest. 
 
DTI analysis. Diffusion MRI datasets were processed with a standard procedure in FSL v5.0.9 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FDT). DTI metrics (fractional anisotropy, FA, and mean 
diffusivity, MD, calculated from weighted least-squares tensor fits) were introduced into the tract-
based spatial statistics (Smith et al., 2006) v1.2 routine with default settings, which generated a 
mean FA skeleton (default FA threshold set to 0.2) to assess white matter tracts, i.e. it did not 
include the substantia nigra or other grey matter regions. Finally, whole-brain group contrasts 
(Parkinson’s disease versus controls) for FA and MD were inferred using Randomise v2.9 (Winkler 
et al., 2014) in FSL with 5,000 permutations of the data and default settings for threshold-free 
cluster enhancement (Smith and Nichols, 2009), i.e. two-dimensional optimisation for tract-based 
DTI analysis. 
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QSM reconstruction 
Multi-channel complex data were combined using a modified adaptive algorithm (Walsh et al., 
2000). Combined phase images were then unwrapped with a continuous Laplacian approach 
(Schofield and Zhu, 2003), and the local field was revealed through global extraction of the 
background field using the spherical mean value filtering method (Schweser et al., 2011) with 
sphere radius of 5 mm. Finally, susceptibility maps were estimated with the morphology-enabled, 
non-linear dipole inversion formulation (Liu et al., 2013) solved by the conjugate gradient method 
on iterative blocks of 500 operations nested in a Gauss-Newton loop with stopping tolerance ratio 
for the outer loop set to 0.01. For consistency with our previous aging study (Acosta-Cabronero et 
al., 2016) using the exact same MRI scan and QSM routine, the Lagrangian multiplier was set to 
λ=1000. Our previous study also suggested reference normalisation is only a small adjustment 
relative to aging effects. In this study, thus, to avoid making assumptions about areas being spared 
in Parkinson’s disease, QSM values were not referenced. 
 
QSM spatial standardisation 
For template creation, radio-frequency bias corrected MPRAGE images were spatially normalised 
using the ‘Greedy-SyN’ approach in ANTs v2.1 (http://stnava.github.io/ANTs) with a maximum of 
90×30×30 multi-resolution iterations and template-update step size set to 0.1 mm. Rigid-plus-affine 
initial alignment was followed by six full runs of the above routine. Subsequently, bias-corrected 
magnitude images were affine co-registered to their corresponding MPRAGE volume. QSM spatial 
standardisation was achieved through the warp composition of the above transformations and third-
order b-spline interpolation. An average template was then calculated across all warped QSMs. 
 
Whole-brain QSM statistical analyses 
Analyses were performed both for signed and absolute QSM. The absolute value was taken to QSM 
to improve statistical conditioning for whole-brain analysis (Betts et al., 2016) and to ameliorate the 
spurious impact of blooming effects, i.e. residuals in the vicinity of steep magnetic susceptibility 
gradients. Smoothing is a requirement in this context to correct for co-registration errors and other 
imperfections, thus a 3D-Gaussian kernel (standard deviation: 3 mm) was applied followed by a 
previously proposed smoothing-compensation strategy (Betts et al., 2016). Whole-brain 
(Parkinson’s disease versus control) permutation analysis was performed with Randomise v2.9 and 
threshold-free cluster enhancement (with ‘-T’ settings, 
http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Randomise) in FSL. Significant clusters were inferred from 
20,000 data permutations and were reported at a family-wise error (FWE) corrected threshold level 
of 0.05. The group comparison was performed in two stages: first, we tested the null-hypotheses 
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that age and sex did not co-vary with group behaviours, which returned a widespread distribution of 
strong positive age effects, whereas the same null hypothesis for sex could not be rejected. The 
second (reporting) stage, therefore, tested whether age-adjusted QSM group medians were equal. 
Finally, to assess whether QSM might predict disease severity, permutation-based whole-brain 
QSM regression analyses versus severity scores, i.e. UPDRS-III and MMSE, were also performed. 
 
Subsequently after analysis, the QSM template and statistical maps were warped into MNI152 
space (Montreal Neurological Institute, McGill University, Canada) using ANTs tools. Affected 
brainstem structures were discerned using Duvernoy’s atlas – the upper pons was identified axially 
on the standardised QSM template across z=-28 mm (in MNI coordinates); high pons at the level of 
the nucleus coeruleus, across z=-25 mm; high pons at the level of the lateral lemniscus, across z=-
22 mm; mesencephalon at the level of the inferior colliculus, across z=-19 mm; mesencephalon at 
the level of the inferior pole of the red nucleus, across z=-13 mm; and mesencephalon at the level 
of the red nucleus, across z=-10 mm. 
 
Regional QSM statistical analysis 
The primary objective of the present study was to map the whole-brain landscape of QSM 
alterations in Parkinson’s disease; post-hoc regional analyses in this context, therefore, aimed at 
providing additional insight into the nature of such alterations. Median QSM values were extracted 
bilaterally from the following structures: caudate nucleus, putamen, globus pallidus, hippocampus, 
amygdala and thalamus – inferred automatically from the study-wise MPRAGE template using 
FSL-FIRST. In addition, QSM data was also extracted from previously validated manual 
segmentations of the red nucleus, substantia nigra and dentate nucleus (Acosta-Cabronero et al., 
2016). Further segmentation of the substantia nigra is particularly complex because its two main 
substructures—dorsally, pars compacta and ventrally, pars reticulata—overlap (Lehericy et al., 
2014). Neuromelanin-rich dopaminergic neurons of the dorsal substantia nigra, however, possess 
differential spin-lattice relaxation properties resulting in T1 shortening effects. Such effects are 
typically too subtle for reliable identification in single subjects but they can be resolved on state-of-
the-art T1-weighted templates. Fig. 1 illustrates the nigral subdivision into dorsal (hyperintense) and 
ventral (hypointense) tiers. Both subregions were traced three-dimensionally using FSL’s image 
viewer (FSLView). Finally, all subcortical regions of interest were eroded by convolution with a 1-
mm radius spherical kernel and were visually inspected on each template-warped QSM to ensure 
partial-volume contamination due to warping errors was not significant.  
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Figure 1. Manual substantia nigra subdivision. Representative sagittal, coronal and axial views of 
the midbrain region for the (A, top) T1-weighted average template, and for nigral subregions 
overlaid onto (A, bottom) T1-weighted, (B) T2*-weighted and (C) QSM templates. Dorsal and 
ventral tiers are denoted by yellow and orange overlays, respectively. 
 
In light of the whole-brain results, a set of cortical regions of interest were also examined; these 
were defined from the gyral-based Desikan-Killiany-Tourville digital atlas (Klein and Tourville, 
2012) overlaid onto the statistical map of QSM group differences. The OASIS-30 template and 
OASIS-TRT-20 joint fusion atlas (in OASIS-30 space) were obtained from Mindboggle’s 
repository (http://www.mindboggle.info/data). The study-wise to OASIS-30 space nonlinear warp 
field was calculated with a deformable b-spline co-registration routine in ANTs 
(‘antsRegistrationSyN’). Desikan-Killiany-Tourville labels were brought into the study space using 
the inverse of such transformation and nearest-neighbour interpolation. Finally, to minimise partial-
volume contamination, each cortical region of interest was intersected with a study-wise grey 
matter mask – the control-average grey matter segment binarised at a grey matter density cut-off of 
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0.5. Grey matter probability segments were inferred from anatomical MPRAGE images using 
SPM12 with default “unified segmentation” settings, and were then spatially normalised using 
ANTs template transforms. The pattern of QSM involvement in the Parkinson’s disease cortex led 
to the selection of six regions of interest – four putative and two control regions. The former were 
lateral occipital, middle temporal, posterior parietal (including inferior and superior parietal lobules 
plus precuneus regions), and rostral middle prefrontal cortex. Pre- and postcentral gyri were 
selected as control regions. 
 
Inter-hemispheric differences were probed using Wilcoxon rank-sum tests, which revealed that 
left/right measurements were comparable across patients and controls both in the cortex and in deep 
grey matter structures (all P>0.15). Thus, to improve measurement stability, median region of 
interest values were averaged across hemispheres and Pearson age-correlation tests were performed; 
these, together with the age effects observed in stage 1 of the whole-brain analysis, confirmed that 
the present age range is sufficiently large to modulate QSM behaviours. Consequently, prior to 
computing Parkinson’s disease-versus-control Wilcoxon rank-sum statistics, QSM values were age-
corrected using the covariance method (Jack et al., 1989). Finally, Pearson correlation tests were 
performed to test the null-hypotheses: QSM in patients does not co-vary with UPDRS-III or 
MMSE. All regional tests were performed two-tailed, and their resulting P-values were Bonferroni-
adjusted to minimise multiple testing effects. 
 
Computing platform 
Except where stated otherwise, processing tasks (including QSM reconstruction and regional data 
analysis) were prototyped and executed in the MATLAB R2012a environment (The Mathworks 
Inc., Natick, MA, USA). 
 
RESULTS 
Structural analyses 
The structural measures—subcortical volumetry, voxel-based morphometry, cortical thickness 
analysis and tract-based DTI statistics—were all negative in the Parkinson’s disease versus age-
matched control group comparison, i.e. they failed to reject the null-hypothesis of equal means or 
medians at an uncorrected statistical threshold of P<0.01. 
 
Whole-brain QSM study 
In contrast, the whole-brain QSM group results (Fig. 2 and Fig. 3) revealed widespread absolute 
susceptibility increases (family-wise error corrected P<0.05) in Parkinson’s disease that involved 
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brainstem, cerebral and cerebellar structures. Largely bilateral abnormalities were identified in the 
rostral pons (z=-34 to -25, y=-25 and x=-8 to 15 mm, including the site of the basal pontis and 
superior areas of the pontine tegmentum); in the superior cerebellar peduncle; caudal 
mesencephalon (z=-22 to -13, y=-16, x=-8 to 8 mm, including dorsal substantia nigra and inferior 
midbrain tegmental areas); temporal lobe structures (z=-43 to 11, y=-58 to -16, x=-44 and 44 mm, 
including portions of superior, middle and inferior temporal, fusiform, parahippocampal, entorhinal 
regions and the hippocampal head, with a marked right bias and largest cluster centred around the 
intermediate part of the right temporal lobe, z=-19 to -13 mm, y=-25 to -16, x=44 mm); occipital 
regions (z=-13 to -53, y=-87 to -58, x=-44 to 44 mm, most intense in left lateral areas but also 
involving lingual, pericalcarine and cuneus cortices); posterior parietal regions (z=17 to 68, y=-70 
to -58, x=-15 to 15 mm, also left lateralised including large sections of the inferior and superior 
parietal lobules, precuneus and isthmus of the cingulate cortex); and prefrontal areas (z=-25 to 50, 
y=24 to 50, x=-44 to 44 mm, most markedly across the rostral middle prefrontal cortex but also 
touching on orbitofrontal areas and the pars triangularis of the inferior frontal lobe). Although more 
patchy, some regions in the insula and cerebellar cortex were also involved. In contrast, QSM in 
primary sensory-motor fields of the precentral and postcentral gyri, most of the remaining insula, 
extra-nigral nodes of the basal ganglia and diencephalic structures did not return statistical 
differences between groups. The opposite behaviour (i.e. reduced absolute susceptibility in 
Parkinson’s disease) was not statistically significant at a whole brain-corrected level. Significant 
clusters for increased signed QSM—albeit less extensive—were highly co-localised with those for 
absolute QSM (not shown). 
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Figure 2. Cluster-based QSM group statistics (N=25 Parkinson’s disease patients vs. N=50 elderly 
controls) for the contrast: age-corrected QSM greater in Parkinson’s disease than in controls. 
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Results were overlaid onto the study-wise QSM template in the MNI coordinate system. 
Red/yellow clusters represent statistical differences at PFWE<0.05. 
 
 
Figure 3. QSM group results with focus on rostral pons and caudal mesencephalic areas. Results 
were overlaid onto the QSM template in MNI space. Semi-transparent blobs represent statistical 
differences at PFWE<0.05. 
 
QSM regression analyses versus symptom severity measures, UPDRS-III or MMSE, did not return 
any significant correlation cluster at the whole-brain level (PFWE<0.05). 
 
Single-subject QSM examination 
Closer inspection of midbrain and cerebellar nuclei demonstrated QSM abnormalities that were 
apparent on visual inspection of individuals (Fig. 4). The most striking effect—consistent with the 
whole-brain results—was observed in the dorsal substantia nigra region. Particularly remarkable 
was the disappearance in most Parkinson’s disease cases of two lateral hyperintense pockets that 
can be readily identified in the caudal region of most healthy subjects (Fig. 3). Increased 
susceptibility, however, was also noticeable in the ventral substantia nigra – chiefly in rostral areas. 
The cerebellar dentate nucleus (Fig. 4) was also abnormal in Parkinson’s disease but in the opposite 
direction with several subjects presenting very little or no contrast on QSM. 
 
	   14	  
 
Figure 4. Magnified views of brainstem and cerebellar nuclei for QSM group-average and 
individual Parkinson’s disease/paired-control subjects. Arrowheads denote nigrosome-1 in dorsal 
substantia nigra (thinner arrows, increased QSM in Parkinson’s disease) and dentate nucleus 
(thicker arrows, decreased QSM in Parkinson’s disease). 
 
Regional QSM study 
In the control group, strong QSM-age dependencies (i.e. statistically significant Pearson 
correlations) were identified in several subcortical and cortical regions of interest including 
putamen, middle temporal and prefrontal structures (Fig. 5). Group statistics were thus calculated 
with age-corrected absolute QSM data (Fig. 6), which returned strong alterations in the substantia 
nigra —mostly driven by increased susceptibility in the dorsal tier though also apparent in ventral 
regions—, lateral occipital, posterior parietal and rostral middle prefrontal cortical regions with 
additional—though less pronounced—increases in the middle temporal gyrus and hippocampus. 
The cerebellar dentate nucleus region of interest again showed the opposite pattern with 
significantly decreased susceptibility. Although effect sizes were overall smaller, regional 
behaviours for signed QSM (not shown) were highly concordant with those reported in Fig. 5 and 6 
for absolute QSM. 
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Figure 5. Regional QSM as a function of age. Median QSM values in Parkinson’s disease plotted 
in relation to their matched-control range. Stars signify the strength of the age-correlation in the 
control group (*** PBonferroni<0.05; ** P<0.01; * P<0.05). To aid comparability, y-axes were clipped 
at six standard deviations around the global control mean. 
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Figure 6. Summary of age-corrected QSM statistics (mean±S.E.M). Stars signify the strength of the 
group difference (**** PBonferroni<0.01; *** PBonferroni<0.05; ** P<0.01; * P<0.05). 
 
In general, consistent with the whole-brain analyses, regional QSM values did not correlate with 
UPDRS-III or MMSE (Supplementary Fig. 1 and Supplementary Fig. 2, respectively), although 
there was a possible suggestion of motor-score correlation in post- (ρ2=0.27, P<0.01) and precentral 
gyri (ρ2=0.29, P<0.01) but these did not remain significant after Bonferroni adjustment. 
 
DISCUSSION 
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Using a whole-brain approach for the first time to map the landscape of magnetostatic alterations in 
Parkinson’s disease, widespread QSM changes across the brainstem and cortex were revealed (Fig. 
2). In the brainstem, abnormalities were identified in the rostral pons, including pyramidal tracts 
and pontine tegmental areas co-localised with the site of the locus coeruleus; the superior cerebellar 
peduncle; and caudal mesencephalon—seemingly spreading across pars compacta/ventral tegmental 
substantia nigra subregions and midbrain tegmental areas, possibly also including dorsal raphe and 
oculomotor nuclei (Fig. 3). Parts of the temporal paralimbic, prefrontal and occipito-parietal cortex 
and, less markedly, insular and cerebellar areas were also involved (Fig. 2). The striatum as well as 
primary motor and somatosensory fields, in contrast, were relatively spared. 
 
Substantia nigra 
Superior pontine and caudal mesencephalic Parkinson’s disease involvement (Fig. 3) was an 
expected result in light of the many past studies that reported extensive Lewy body pathology and 
loss of pigmented neurons in brainstem nuclei such as locus coeruleus and substantia nigra pars 
compacta (Hirsch et al., 1988; Braak et al., 2004). Past reports have shown that iron overload in 
Parkinson’s disease substantia nigra can be readily identified by the absence of a bilateral pocket of 
low paramagnetism located in the dorsolateral region – a caudal substantia nigra subregion 
commonly designated as substantia nigra nigrosome-1 – detectable both with 3T (Schwarz et al., 
2014) and 7T MRI (Kwon et al., 2012; Blazejewska et al., 2013; Lehericy et al., 2014). The 
nigrosome-1 is a large cluster of melanin-rich dopaminergic neurons that do not require as much 
iron for their normal activity as their adjacent neighbours (Lehericy et al., 2014). In Parkinson’s 
disease, however, nigrosome-1 dopaminergic neurons progressively scavenge excess iron (Good et 
al., 1992; Oakley et al., 2007) and degenerate (Fearnley and Lees, 1991; Damier et al., 1999); 
observations consistent with the present study in which nigrosome-1 of Parkinson’s disease patients 
appeared overloaded with iron, which might be more readily detectable on coronal views (Fig. 4). 
To our knowledge—although this was not our primary objective, hence image resolution was 
suboptimal for this purpose—this is the first report of nigrosome-1 visualisation with QSM. In 
future, quantitative susceptibility evaluations of nigrosome-1 load in Parkinsonism with higher 
resolution MRI prescriptions optimised for midbrain imaging are warranted. On a different note, it 
is also worth highlighting that substantia nigra free water levels estimated with a diffusion MRI bi-
tensor model have recently been proposed as a novel biomarker in Parkinson’s disease (Ofori et al., 
2015) – a selective pattern of progressive free water elevation that stands in stark contrast to the 
more widespread involvement found for other extra-pyramidal disorders (Planetta et al., 2016). 
Combining QSM and free water levels—as surrogates for iron content and cellularity, 
respectively—in future studies may, therefore, offer added value in exploring nigral integrity. 
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Globus pallidus 
In contrast to the substantia nigra, only a non-significant QSM increase was observed in the globus 
pallidus of Parkinson’s disease patients. Notably, post-mortem reports of pallidal iron content are 
inconclusive; while some studies have shown an increase in Parkinson’s disease (Chen et al., 1993), 
others showed normal levels (Riederer et al., 1989; Sofic et al., 1991) or even reductions (Dexter et 
al., 1991). Differences across experimental procedures and quantification techniques could explain 
the discrepancy (Hare et al., 2012), though a key possibility might be inferred from one study 
(Griffiths et al., 1999) that revealed iron content decreased in pars interna and increased in pars 
externa in Parkinson’s disease. It is conceivable, therefore, these effects could cancel each other 
when studying the whole globus pallidus with regions of interest or by the effect of spatial 
smoothing (a necessary step in co-registration based analyses of the whole brain). There may also 
be a temporal dimension that could explain the discordant pallidal iron results in Parkinson’s 
disease: QSM elevation has been reported in moderate—mean UPDRS-III=44.5±13.1—but not 
early disease stages—mean UPDRS-III=22.8±11.7 (Guan et al., In Press, DOI: 10.1002/nbm.3489, 
available online 8 February 2016)—consistent with the present negative pallidal results in a 
Parkinson’s disease cohort with a mean UPDRS-III of 16.3±8.0, therefore suggesting that pallidal 
iron loading may be a relative late disease feature. 
 
Striatum 
Another relevant negative in the present study was the lack of significant alterations in the normally 
iron-rich striatum. This negative is compatible with many post-mortem (Riederer et al., 1989; 
Dexter et al., 1991; Sofic et al., 1991) and in vivo region of interest studies using the apparent 
proton transverse relaxation rate i.e. R2* (Martin et al., 2008; Du et al., 2012; Barbosa et al., 2015; 
He et al., 2015; Murakami et al., 2015), homodyne-filtered phase mapping (Han et al., 2013; Kim 
and Lee, 2014) or QSM (Barbosa et al., 2015; He et al., 2015; Murakami et al., 2015). This 
observation finds resonance with the view that dopamine responsiveness in Parkinson’s disease 
relates to the preserved striatal targets of the degenerating nigrostriatal dopaminergic neurons, 
which could also lead to the prediction that Parkinson-plus diseases such as progressive 
supranuclear palsy and multiple system atrophy might show additional QSM changes in the corpus 
striatum (Dexter et al., 1991; Han et al., 2013). 
 
Cerebellum 
An interesting observation in the age-corrected region of interest analysis was a significant QSM 
reduction in the cerebellar dentate nucleus (Fig. 6). This structure has typically not been considered 
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in post-mortem Parkinson’s disease analyses, but there is at least one precedent where a marked 
iron reduction was found in the dentate nucleus (Riederer et al., 1989), though the observation was 
not discussed further. In health, the cerebellar dentate is one of the most iron-rich structures in the 
brain (Hallgren and Sourander, 1958) and therefore returns high QSM values (Acosta-Cabronero et 
al., 2016). In the elderly, however, dentate susceptibility estimates become dispersed—in 
comparison to young adults—including a small minority of cases with very low values (Acosta-
Cabronero et al., 2016). It appears that low values become very prevalent in Parkinson’s disease. 
The reduction in some individuals was extreme in the present study (Fig. 4 and 5); whether this 
might have phenotypic significance should be a topic for future research. The patient cohort in this 
study was predominantly akinetic-rigid Parkinson’s disease (only three tremor-dominant cases), 
thus decreased QSM appears to be concordant with a recent study that has hinted at dentate QSM 
being associated with phenotypic differences in that tremor-predominant cases returned increased 
values, whereas there was a trend to reduced susceptibility in akinetic-rigid Parkinson’s disease (He 
et al., In Press, DOI: 10.1002/nbm.3554, available online 18 May 2016). One other study found no 
changes in the dentate in Parkinson’s disease, although the acquisition was very brief and relatively 
low resolution therefore risking loss of sensitivity (Guan et al., In Press, DOI: 10.1002/nbm.3489, 
available online 8 February 2016). There is growing interest in the role of the cerebellum in 
Parkinson’s disease with the discovery of disynaptic pathways linking cerebellum to basal ganglia 
(Bostan et al., 2013) and with numerous studies highlighting cerebellar hyperactivation during 
motor tasks or increased resting functional connectivity – reviewed elsewhere (Wu and Hallett, 
2013). Physiological changes such as these may be secondary or compensatory but the present 
finding of apparent loss of iron content in the dentate points to local cerebellar alterations—a 
finding that should be investigated further histologically.  
 
Cortex 
An advantage of the present MRI approach over other established means of probing brain iron such 
as histochemical analysis, staining methods or transcranial sonography is that MRI can image the 
whole brain in a few minutes, thus making it an ideal tool to characterise the cortical pattern of iron 
deposition in vivo. The present whole-brain results (Fig. 2)—the first of their kind in Parkinson’s 
disease—revealed a distribution of QSM abnormalities in the cortex that was in close agreement 
with the suspected landscape of Lewy inclusion pathology (Hughes et al., 1992; Braak et al., 2004) 
and glucose hypometabolism in autopsy-confirmed Lewy body disease (Minoshima et al., 2001). In 
clinical stages, these predict concurrent involvement of limbic and paralimbic structures of the 
temporal lobe, prefrontal cortex and isocortical sensory-association areas with relative sparing of 
primary sensory areas—a distribution highly consistent with the QSM results in this study. Such 
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concordance between markers of pathology, iron accumulation and neuronal loss does not yet 
clarify whether iron is cause or consequence of Parkinson’s disease degeneration, it cannot resolve 
either whether iron dysregulation occurs through uptake, storage or transport mechanisms, or 
whether excess iron is in free form or bound to macromolecules, but reinforces the notion that in 
Parkinson’s disease there is a deleterious cocktail of Lewy inclusions and iron elevation across the 
isocortex. The causative theory that iron accumulation is an upstream event to Lewy pathology, 
however, could be entertained. It could be argued that although the distribution of cortical increase 
in QSM in the present study shows homology with the known distribution of glucose 
hypometabolism and Lewy pathology once this pathology has reached the neocortex, it does not 
follow that pathological burden causing neuronal dysfunction and iron accumulation are 
contemporaneous events. In fact, given that the current cohort generally had preserved cognition, it 
is possible that the cohort were not yet significantly affected by neocortical Lewy pathology—
symptomatic Parkinson’s disease is thought to begin with Braak stage 4 α-synuclein pathology 
(Braak et al., 2003) in which the neocortex is yet to be affected. There is no way at present to 
directly investigate this in vivo because imaging techniques that visualise α-synuclein are not yet 
available. Though it would be intriguing to investigate, post-mortem, whether increases in 
neocortical iron concentration are detectable in Parkinson’s disease brains without neocortical Lewy 
pathology (i.e. Braak stage<5). Nonetheless, even if iron imbalance was an indirect consequence of 
other primary causes, a mirroring distribution would still be highly relevant for the purpose of 
disease monitoring as it would mean iron mapping could act as proxy signature of cortical 
pathology. 
 
Biomarker relevance 
The QSM findings stand in stark contrast to the lack of significant findings using conventional MRI 
methods namely voxel-based morphometry, cortical thickness analysis, subcortical volumetry and 
tract-based DTI analysis. The negative findings with these methods were not unexpected; for 
instance, even in dementia with Lewy bodies, structural imaging to detect atrophy is largely 
unremarkable (Whitwell et al., 2007) while previous tract-based DTI studies have also been 
negative (Worker et al., 2014). Though notably, diffusion MRI using a bi-tensor model, as 
previously discussed, could offer a sensitive marker to study the substantia nigra (Ofori et al., 
2015), which is usually excluded from DTI analyses due to low diffusion anisotropy and other 
reliability concerns. The absence, however, of consistent findings with standard structural MRI/DTI 
methods highlights the potential of probing tissue iron across the whole brain with QSM as a useful 
biomarker in Parkinson’s disease. 
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Note on QSM interpretations 
A broad assumption in this study was that QSM alterations in Parkinson’s disease reflect changes in 
iron content. Such interpretation, however, merits further discussion on the basis that the intrinsic 
magnetostatic properties of human brain tissue are not be driven by iron alone. Copper(II) and 
manganese compounds are magnetically reactive and could perturb the susceptibility measurement; 
although with concentrations 15 and 50 times lower, respectively, than iron in the substantia nigra 
(Krebs et al., 2014), it is highly improbable they could have played a significant role in the present 
results. Furthermore, post-mortem studies have suggested that copper levels are slightly reduced in 
the substantia nigra in Parkinson’s disease (Dexter et al., 1991; Davies et al., 2014), while 
manganese levels are largely unaltered (Dexter et al., 1991). Abnormally high levels of zinc, in 
contrast, have been detected in several post-mortem Parkinson’s disease brain regions. Zinc too, 
however, is scarce relative to iron content and does not have an unpaired electron configuration; 
consequently, the impact of zinc on QSM can also be discarded. Diamagnetic alkaline earth metals, 
calcium and magnesium, are more abundant in human brain tissue than the aforementioned 
transition metals, with regional concentrations in post-mortem tissue similar—often greater—than 
those for iron (Krebs et al., 2014). Conceivably, the effect of diamagnetic mineralisation could 
reduce QSM sensitivity to iron-related effects. Signed QSM, however, although less sensitive 
overall than absolute QSM presumably due to its greater vulnerability to neighbouring 
contamination (Betts et al., 2016), returned increased susceptibility—consistent with increased iron 
content—across all affected areas. The exception was the dentate nucleus meaning that, in addition 
to a loss of iron, micro-calcifications could explain our QSM observations, and should thus be 
considered as a plausible theory in future post-mortem studies. 
 
Three post-mortem validation studies that, to date, have been carried out to investigate the 
relationship between QSM and tissue iron concentrations (Langkammer et al., 2012; Zheng et al., 
2013; Sun et al., 2015) should also be considered in interpreting the present study. The conclusion 
from these studies was that ferric iron, presumably stored in glial ferritin, is the dominant source of 
magnetic susceptibility in metal-laden deep brain nuclei. In the cerebral cortex, however, it has been 
shown that the myeloarchitecture can modulate local tissue susceptibility (Fukunaga et al., 2010; 
Stüber et al., 2014). It is therefore plausible that demyelination processes – yielding a net increase 
in paramagnetism – could drive QSM effects in areas of relatively low iron concentration, e.g. 
prefrontal cortex. Both studies, however, demonstrated that ferritin iron co-localised with intra-
cortical myelin is the dominant source of local susceptibility – approximately two thirds of the 
overall contrast proportion in grey matter (Stüber et al., 2014) – suggesting, therefore, only a 
massive myelin-driven susceptibility effect could perturb the measurement. In future, a recently 
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proposed multivariate model could be applied to disentangle iron/myelin contributions using multi-
contrast information (Stüber et al., 2014). All of the above, nonetheless, suggests the present in vivo 
results are most likely driven by changes in iron content, although QSM’s inability to provide 
information about the exact cellular distribution or the valency of iron ions means the present 
results cannot discern whether QSM alterations in Parkinson’s disease are primarily driven by 
excess free iron, greater ferritin numbers, greater iron loading within ferritin or neuromelanin, 
hemosiderin burden, or whether they represent neuronal or glial iron accumulation. 
 
Finally, other technical limitations must be highlighted. The medulla oblongata has been postulated 
as one of the earliest sites of Lewy pathology in the Parkinson’s disease cascade (Braak et al., 
2004), though here it did not return a significant QSM alteration. A plausible explanation for such 
absence could be that baseline iron levels are very low in medullar nuclei, thus small disease-related 
alterations—potentially large in relative terms—may lie undetected with current technology. In 
contrast, one should be careful of not over-interpreting whole-brain results in small anatomical 
structures. Prior to performing statistics, QSM data was spatially smoothed to account for possible 
errors in spatial normalisation, and although a smoothing-compensation strategy was applied, one 
should assume a degree of spatial uncertainty for the resulting clusters. This is particularly relevant 
to Braak stage 1-2 (Braak et al., 2004) brainstem nuclei such as the motor nucleus of the vagus 
nerve, locus coeruleus or raphe nucleus that are probably too small to be reliably assessed using the 
present whole-brain methodology. On a final note, we must highlight that in the present study we 
were unable to establish QSM correlates of symptom severity measures, i.e. UPDRS-III and 
MMSE. Given the narrow spread of severity scores for the patient cohort under investigation 
(particularly for MMSE, see Supplementary Material) and a relatively low number of subjects for 
regression analyses, the risk of false-negative associations is very high. The relationship of QSM 
alterations to clinical parameters warrants a future investigation with greater statistical power and 
variance in the clinical data. 
 
Conclusions 
This study revealed a spatial distribution of QSM alterations in Parkinson’s disease highly 
consistent with the landscapes of glucose hypometabolism and Lewy pathology that are known to 
emerge as the disease evolves. In contrast to QSM, no significant effects were observed with 
standard structural MRI and microstructural DTI measurements. These results, therefore, 
demonstrate the relevance of mapping the biochemical environment of the whole Parkinson’s 
disease brain in vivo, and provide new insights into the behaviour of QSM as a disease biomarker. 
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MRI’s safe and non-invasive nature means, in addition, that QSM might be suitable for longitudinal 
monitoring in clinical trials. 
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Supplementary Material 
 
 
 
Supplementary Figure 1.  Regional QSM versus UPDRS-III. Age-adjusted median QSM values 
in Parkinson’s disease plotted as a function of motor status. Stars signify the strength of the 
correlation in the patient group (** P<0.01). 
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Supplementary Figure 2.  Regional QSM versus MMSE. Age-adjusted median QSM values in 
Parkinson’s disease plotted as a function of cognitive status. 
 
